The legal inquiry follows a sharp decline in Disc Medicine’s market value on February 13, 2026. On that day, the company’s stock price plummeted 22% after the U.S. Food and Drug Administration issued a Complete Response Letter regarding the developer’s bitopertin program. Federal regulators indicated they could not approve the new drug application, citing outstanding uncertainties that require additional clinical evidence to resolve.

Rosen Law is now organizing a prospective class action to recover investor losses. The firm, which operates on a contingency fee basis, invites affected shareholders to submit information through its legal portal or contact Phillip Kim directly. While the firm touts a history of high-profile settlements in securities litigation, the legal action remains in the investigative stage, and previous outcomes do not serve as a guarantee for future results in this specific case.